MiR-320c regulates gemcitabine-resistance in pancreatic cancer via SMARCC1.

ABSTRACT:

Background

Gemcitabine-based chemotherapy is the standard treatment for pancreatic cancer. However, the issue of resistance remains unresolved. The aim of this study was to identify microRNAs (miRNAs) that govern the resistance to gemcitabine in pancreatic cancer.

Methods

miRNA microarray analysis using gemcitabine-resistant clones of MiaPaCa2 (MiaPaCa2-RGs), PSN1 (PSN1-RGs), and their parental cells (MiaPaCa2-P, PSN1-P) was conducted. Changes in the anti-cancer effects of gemcitabine were studied after gain/loss-of-function analysis of the candidate miRNA. Further assessment of the putative target gene was performed in vitro and in 66 pancreatic cancer clinical samples.

Results

miR-320c expression was significantly higher in MiaPaCa2-RGs and PSN1-RGs than in their pa

SUBMITTER: Iwagami Y 

PROVIDER: S-EPMC3721395 | biostudies-literature | 2013 Jul

REPOSITORIES: biostudies-literature